Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + IBI376 in relapsed or refractory peripheral T-cell lymphoma
ChiCTR2100047979Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and parsaclisib in peripheral T-cell lymphoma (PTCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective response rate. Planned start May 2021; status: not yet recruiting.
02
Drugs
sintilimabparsaclisib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2100047979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047979.